Sangamo Therapeutics Files for Chapter 11 Bankruptcy, Strikes Asset Deals with Eli Lilly and Astellas
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
/ 87 items
#LLY↓
Eli Lilly Acquires 4E Therapeutics to Strengthen Non-Opioid Pain Pipeline
Eli Lilly has acquired 4E Therapeutics, a neuroscience biotech developing non-opioid treatments for chronic pain. This marks Lilly’s 11th deal of 2026 and strengthens its non-opioid pain pipeline.
Eli Lilly Stock Surges as Retatrutide Delivers 28% Weight Loss and Major Relief for Sleep Apnea & Knee Pain
Lilly stock jumps as new obesity drug helps people lose ~30% body weight and improve health, showing strong promise for future treatment.
Lilly and Ascidian Sign $1.9B Deal to Bring RNA Gene Editing to Genetic Kidney Diseases
Eli Lilly teams with Ascidian to use RNA editing to treat rare kidney diseases without changing DNA.
Eli Lilly Spends Nearly $4 Billion to Enter the Vaccine Market
Eli Lilly is buying 3 vaccine firms for up to $4B to expand beyond diabetes and obesity into infectious disease vaccines.
Eli Lilly’s Retatrutide Delivers 28.3% Weight Loss in Phase 3 Trial, Analysts Stay Bullish
Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.